Abstract

<div>Abstract<p><b>Background:</b> Blood miRNAs are a new promising area of disease research, but variability in miRNA measurements may limit detection of true-positive findings. Here, we measured sources of miRNA variability and determine whether repeated measures can improve power to detect fold-change differences between comparison groups.</p><p><b>Methods:</b> Blood from healthy volunteers (<i>N</i> = 12) was collected at three time points. The miRNAs were extracted by a method predetermined to give the highest miRNA yield. Nine different miRNAs were quantified using different qPCR assays and analyzed using mixed models to identify sources of variability. A larger number of miRNAs from a publicly available blood miRNA microarray dataset with repeated measures were used for a bootstrapping procedure to investigate effects of repeated measures on power to detect fold changes in miRNA expression for a theoretical case–control study.</p><p><b>Results:</b> Technical variability in qPCR replicates was identified as a significant source of variability (<i>P</i> < 0.05) for all nine miRNAs tested. Variability was larger in the TaqMan qPCR assays (<i>SD</i> = 0.15–0.61) versus the qScript qPCR assays (SD = 0.08–0.14). Inter- and intraindividual and extraction variability also contributed significantly for two miRNAs. The bootstrapping procedure demonstrated that repeated measures (20%–50% of <i>N</i>) increased detection of a 2-fold change for approximately 10% to 45% more miRNAs.</p><p><b>Conclusion:</b> Statistical power to detect small fold changes in blood miRNAs can be improved by accounting for sources of variability using repeated measures and choosing appropriate methods to minimize variability in miRNA quantification.</p><p><b>Impact:</b> This study demonstrates the importance of including repeated measures in experimental designs for blood miRNA research.</p><p>See all the articles in this <a href="http://cebp.aacrjournals.org/content/23/12.toc#CEBPFocus" target="_blank"><i>CEBP Focus</i></a> section, “Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology.”</p><p><i>Cancer Epidemiol Biomarkers Prev; 23(12); 2658–66. ©2014 AACR</i>.</p></div>

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call